H.C. Wainwright raises Genmab stock price target to $70 on trial data
H.C. Wainwright raised its price target for Genmab (GMAB) to $70 from $60, maintaining a Buy rating. The move follows positive Phase 3 trial results for petosemtamab, showing a 50% reduction in death risk. Genmab's stock has risen 29% in a week. The company reported Q2 2026 earnings of $4.91 per share, beating estimates. Analysts from Guggenheim, JPMorgan, and Morgan Stanley also updated their targets and ratings.
How this was made
The 30-second read
Why it matters
The data represents a material clinical milestone that can materially affect Genmab's valuation and market perception.
Market read
Genmab's trial success is a catalyst for biotech equities, potentially influencing peer valuations and sector momentum.
What to watch
Potential pricing pressure from upcoming competitor trials and reimbursement uncertainties could temper upside.
Background
The article summarizes analyst upgrades and price target revisions following Genmab's Phase 3 trial success.
Ticker impact
Genmab announced positive Phase 3 LiGeR-HN1 trial results, driving a 29% share surge and prompting analysts to raise price targets.
upward pressure as investors price in higher approval odds and revenue potential
The trial met primary endpoints with strong hazard ratio and odds ratio improvements, and analysts raised targets, indicating strong bullish sentiment.
Market effects
Boosts biotech sector sentiment, especially companies with late‑stage oncology pipelines.
European biotech markets may see modest gains as a Danish‑listed firm reports strong data.
Highlights continued investor appetite for immuno‑oncology therapies worldwide.
Counterpoint
Some investors may question durability of the surge if regulatory timelines extend or competition intensifies.
Key entities
- companyGenmab A/S
Danish biotech firm developing antibody therapies.
- analystH.C. Wainwright
Equity research firm raising price target to $70.
